ClinicalTrialsFinder

Hormone Receptor Positive HER-2 Negative Breast Cancer Clinical Trials in Düsseldorf, North Rhine-Westphalia

1 recruitingDüsseldorf, North Rhine-Westphalia, Germany

Showing 1–1 of 1 trials

Recruiting
Phase 2

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Advanced or Metastatic Breast CancerBRCA1 MutationBRCA2 Mutation+1 more
GBG Forschungs GmbH176 enrolled36 locationsNCT06201234